Compare Dyne Therapeutics Inc. Common Stock (DYN) vs PACCAR Inc. Common Stock (PCAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs PACCAR Inc. Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while PACCAR Inc. Common Stock trades at $109.39 (market cap $56.84B). The key difference: PACCAR Inc. Common Stock is far larger — about 19.9× Dyne Therapeutics Inc. Common Stock's market cap, and PACCAR Inc. Common Stock pays a 1.3% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and PACCAR Inc. Common Stock for 6 Days on average.
| DYN | PCAR | |
|---|---|---|
Market Cap | $2.86B | $56.84B |
Volume | 3,341,579 | 2,800,805 |
Sector | Health | Industrials |
52-Week High | $26.78 | $138.21 |
52-Week Low | $14.60 | $94.15 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.18B | $62.70B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
PACCAR (PCAR) trades at $107.98, down 0.14% with bearish technical signals but strong fundamentals including 9% net income margin and 12.76% ROE. Recent earnings beat expectations in Q2 2026 with $1.43 EPS versus $1.36 expected. The company maintains stable cash flows with $4.3B operating cash flow projected for 2026 and recently declared a $0.35 quarterly dividend payable December 2026.
PCAR presents a mixed outlook with Wall Street consensus price target of $134.83 suggesting 25% upside potential, though technical indicators show bearish momentum. Key risks include sector sensitivity to interest rates and industrial cyclicality, while opportunities lie in the company's strong profitability metrics and defensive non-trucking segments representing over 60% of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About PACCAR Inc. Common Stock
PACCAR designs and manufactures heavy-duty trucks under brands including Peterbilt, Kenworth, and DAF. It also provides parts, financial services, and technology for commercial vehicles.
Read more on PCAR →
